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There are only a few studies assessing the relationship between adherence rate to ICS, as as-
sessed by electronic monitoring, and the level of asthma control in childhood. The present
study was carried out to examine the relationship between adherence to beclomethasone di-
proprionate (BDP) as well as other factors related to poor asthma control. In this prospective
cohort study, 102 steroid naı¨ve randomly selected subjects with persistent asthma, aged 5e14
years were prescribed 500e750 mg daily of BDP-CFC and followed during one year. Adherence
to BDP was measured electronically in the 4th, 8th and 12th months of study. The level of
asthma control was classified as either controlled or uncontrolled instead of the current three
categories recommended by the Global Initiative for Asthma (GINA). Mean adherence rate was
higher in patients with controlled asthma during follow-up, but went down from 60.4% in the
4th month to 49.8% in the 12th month (p Z 0.038). Conversely, among patients with uncon-
trolled asthma, the mean adherence rate decreased from 43.8% to 31.2% (p Z 0.001). Multi-
variate analysis showed that the level of asthma control was independently associated to
the adherence rate in all follow-up visits (p-values equal or lower than 0.005). The level of
asthma control was directly proportional to adherence rate. Our results suggest that a BDP
daily dose by 300 mg seems to be enough to attain control over mild and moderate persistent
asthma, including exercise induced asthma.
ª 2011 Elsevier Ltd. All rights reserved.of Pediatrics, Medical School, Federal University of Minas Gerais, Avenida Alfredo Balena, 190/Room
. Tel.: þ55 31 34099772; fax: þ55 31 34099664.
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Adherence rate to BDP & the level of asthma control 339Introduction asthma control, only two categories were adopted in theAdherence is the process by which a person follows
a prescription and recommendations for a regimen of care.
Rates of non-adherence in the treatment of asthma
commonly range 30e70%1 and consequently suboptimal
adherence can significantly contribute to asthma exacer-
bations.1e5 For instance, Milgrom et al. demonstrated that
mean adherence to ICS therapy e measured through elec-
tronic monitoring e of children requiring a prednisone burst
was 13%, compared to 68% adherence for children without
severe exacerbations.2
Recent versions of international guidelines have focused
on asthma control, through the following major compo-
nents: frequency of patient symptoms (daytime and night-
time, including nighttime awakening), interference with
normal activity, frequency of exacerbations and short-
acting beta2-agonist use, and lung function. Accordingly,
asthma should be considered controlled when these
abnormalities are absent; partly controlled when at least
one is present in at least a week; and uncontrolled asthma
when three or more are present in a least a week.4
However, in a chronic disease like asthma, some degree
of suboptimal adherence can be tolerated within certain
limits. The estimate of this acceptable level of non-
compliance that can still keep the disease under control
is of great interest to real-life strategies.
The present study was carried out to assess the rela-
tionship between the adherence rate to beclomethasone
dipropionate (BDP) e assessed through an electronic
monitor e and the level of asthma control as well as other
factors related to poor asthma control. Works on this
subject in pediatric patients are still scarce.Methods
Study design, duration and setting
This is an ambulatory-based prospective randomized cohort
study, spanning 12 months, where only patients with
persistent uncontrolled and untreated asthma were
admitted. They were treated and followed at the Campos
Sales Outpatient Referral Clinic, linked to the Belo Hori-
zonte Municipal Public Health Authority (BHMPHA) network.
According to the protocol standardized by the BHMPHA, the
participants received beclomethasone diproprionate (BDP)-
CFC, the cheapest ICS available in Brazil, free of charge
(Clenil, Chiesi Brazil, 250 mg/puff, 200 actuations/
canister) and a pear-shaped plastic valved spacer
(Flumax, Flumax Medical Equipments, Brazil). A pressure-
actuated electronic monitor attached to the BDP-metered-
dose inhaler (Doser CT, Meditrack Products, USA) was also
given for use throughout the 12-month follow-up. It is
important to note that formulations containing 100 and
200 mg of BDP are not commercialized in Brazil.
Levels of asthma control and follow-up
As the main goal of asthma treatment is to achieve a normal
or near normal life, or, in other words, achieve completefollow-up visits: controlled and uncontrolled asthma. The
two categories represent, respectively, the definitions of
controlled asthma on one hand, and on the other, partially
controlled and uncontrolled asthma according to GINA
classification.4
Thus, controlled or uncontrolled asthma were pre-
defined as (1) absence or presence of daytime symptoms,
limitations of activities, nocturnal symptoms/awakening,
need for reliever/rescue treatment, and/or exacerbations
in the four weeks preceding the scheduled follow-up visits
for the 4th, 8th and 12th months and/or (2) FEV1 equal or
higher than and lower than 80% of the predicted values.
The forced expiratory spirometry was performed within two
weeks of the follow-up visits in those able to perform the
maneuver, respectively.
Inclusion and exclusion criteria
Weadmitted children and adolescents aged 5e14 years,with
persistent uncontrolled asthma, whose parents or legal
guardians were able to read and write. Exclusion criteria
were intermittent asthma, previous use of ICS or other anti-
asthmamedication in the four months prior to the study, and
other chronic and/or systemic concurrent disease.
Therapeutic regimens
Only albuterol-pMDI (provided for quick relief of symptoms
as needed), and BDP-CFC-pMDI (250 mg/puff, as controller
medication) were given for free by the BHMPHA. One puff
of BDP was prescribed twice (i.e. 500 mg/day, 1 puff at
morning and at bedtime) or three times daily (i.e. 750 mg/
day, 1 puff at morning and two puffs at bedtime) just after
protocol admission depending on asthma severity, as
follows: mildemoderate and severe persistent,
respectively.
For patients receiving 500 mg/day and 750 mg/day
a stepping up strategy of, respectively, 750 mg/day and
1000 mg/day were pre-defined as long as optimal adherence
rate was verified and asthma control was not achieved with
the initial doses. That simplified and adapted therapeutic
regimen was adopted because of all participants were from
very low income families and for that reason they could not
afford either ICS in a single inhaler or ICS and long acting
beta-agonists combinations. Patients and/or their care-
givers taught and retaught inhaler/spacer technique in
every follow-up visit.
Adherence rate assessment
Cumulative adherence rates verified in the first 4 months
after enrollment, between 4 and 8 months and between 8
and 12 months were recorded through Doser CT (MedTrack
Products, USA). Doser CTs were collected at 30e60 day
intervals. One Doser CT per month was dispensed free of
charge to each subject at every follow-up visit, and were
asked to return them every two months.
Adherence rates were calculated according to the
following formula: number of puffs used/numbers of puffs
prescribed  100.
Table 1 Baseline characteristics of the participants
(N Z 102).
Characteristic N %
Sex
Male 60 58.8
Female 42 41.2
Age group (years)
5e6 53 52.0
More than 6 49 48.0
Mother’s schooling level (years)
Up to 8 67 65.7
More than 9 35 34.3
Father’s schooling level (years)
Up to 8 67 65.6
More than 9 35 34.4
Mean family monthly income (US$)
Up to 100 57 55.8
More than 100 45 44.2
Duration of asthma (years)
Up to 3 56 54.9
More than 4 46 45.1
Previous non-scheduled emergency department visits
Yes 90 88.2
No 12 11.8
Previous hospitalizations due to acute asthma
Yes 44 44.8
No 58 59.2
BDP-CFC dosage after admission (mg/daily) on the study
protocol
500 95 93.1
750 7 6.9
Pre-bronchodilator FEV1 at admission
a (% predicted)
<80 29 67.4
80 13 32.6
a 43 out of 102 subjects were able to perform spirometry.
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Descriptive statistics were used to report the baseline
characteristics of the studied population. The mean
adherence rate to BDP was plotted against the level of
asthma control by box-plot for the adherence with Doser
CT in the 4th, 8th and 12th month and respective mean
(standard deviations), median, range (minimum toTable 2 Adherence rate (%) stratified by level of asthma contr
Level of asthma control Mean (SD) Adherence
Min
4th month
Controlled 60.4 (17.3) 41.0
Uncontrolled 43.8 (21.5) 10.0
8th month
Controlled 56.2 (22.1) 21.0
Uncontrolled 39.0 (21.0) 4.0
12th month
Controlled 49.8 (20.8) 9.0
Uncontrolled 31.2 (12.6) 8.0maximum) and 1st and 3rd quartiles distributions.
Comparison of asthma control level was done using
Student’s t and ManneWhitney’s tests.
The predictive independent variables in the logistic
model were incorporated only for variables whose p-values
were 0.25 in the univariate analysis. Each non-significant
variable was excluded through stepwise strategy and
a significance level of 5% was used to ensure a variable
remained in the final model. Final model appropriateness
was assessed by HosmereLemeshow test.
Sample size assumptions
Based on the scarce available data6e8 we assumed that the
mean adherence rate to achieve controlled asthma should
be at least 45%, (with SD equal to 15%) whereas an adher-
ence of 35% (with the same SD) would lead to a partly
controlled/uncontrolled asthma (mean difference of 10%).
Assuming an alpha and beta error of 0.05 and 0.20 (80%
power), respectively, a minimum of 36 patients in both
categories were necessary for statistical analysis. Taking
into account a dropout rate of 50%, a total of 108 patients
should be recruited.
Ethical aspects
The study protocol and informed consent were approved by
the Committee of Ethics in Research of the Universidade
Federal de Minas Gerais.
Results
A hundred and two patients were recruited for the study.
Their baseline characteristics are displayed in Table 1.
There was a predominance of male patients (58.8%),
aged up to six years (52.0%), whose parents completed
elementary education (65.7% and 65.4% respectively). Their
monthly family income were lower than US$100 (56.4%),
demonstrating that they can’t afford any anti-asthmatic
drug. As to the clinical characteristics, there is a greater
frequency of patients with asthma for less than 3 years
(55.0%), with at least one visit to emergency services
(88.2%) and one hospitalization (44.8%) before protocol
admission. Only 7 (6.9%) received 750 mg daily of BDP after
admission on the study protocol.ol in the 4th, 8th, and 12th month (N Z 102).
1st. Q Median 3rd. Q Max
49.5 54.0 69.5 97.0
29.3 41.0 53.8 99.0
42.0 50.0 70.0 100.0
24.0 34.5 54.0 95.0
24.5 47.0 55.0 100.0
22.5 31.5 38.0 76.0
Figure 1 Adherence rate to BDP (%) and the corresponding
level of asthma control during the follow-up appointments
(A Z 4th month; B Z 8th month; and C Z 12th month).
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able to perform forced expiratory maneuver. For the
remaining 59 subjects the level of asthma control was
based on clinical grounds.
Table 2 shows the distribution of the level of asthma
control according to the adherence rate measured during
the three follow-up visits.
It is important to note that the minimum of 36 patients
(see sample size assumptions) in each category, i.e.
controlled and uncontrolled, was effectively reached in the
8th (42 and 60) and the 12th (64 and 38) month, respectively.
From the baseline, the proportion of controlled asthma
increased progressively to 17.6%, 41.2% and 62.7%, whereas
the frequency distribution of uncontrolled asthma
decreased from 100% at admission (see inclusion criteria) to
82.4%, 58.8% and 37.3% in the 4th, 8th and 12th month,
respectively (data not shown).
There were higher values for both the mean and the
median adherence rate in patients with controlled asthma
in the 4th, 8th, and 12th month of follow-up. Among them
the mean adherence rate was reduced from 60.4% (on the
4th month) to 49.8% (on the 12th month, p-valueZ 0.038),
whereas among patients with uncontrolled asthma, the
mean adherence rate reduced from 43.8% (on the 4th
month) to 31.2% (on the 12th month, p Z 0.001). As the
majority of the participants were prescribed 500 mg as an
average daily dose, they gained asthma control with
approximately 270 mg (54% out of 500 mg) and 235 mg (47.0%
out of 500 mg) in the 4th and 12th month respectively.
Conversely, daily doses lower than 219 mg (43.8% out of
500 mg) on the 4th and 156 mg (31.2% out of 500 mg) on the
12th month were insufficient to achieve asthma control.
Analysis of the evolution of FEV1 results among the 43
patients who were able to perform forced expiratory
maneuver has consistently pointed to the same direction of
symptomatology, i.e., FEV1 from 81.8% to 90.6% of the
predicted were achieved with adherence rate from 42.9% to
46.7% in each of the three follow-up visits (data not shown).
On the other hand, to attain both, functional and clinical
control, including exercise induced asthma, there was not
necessarily a mean adherence rate increase in the same
proportion because the rate dropped from 60.4% to 49.8%
(p Z 0.038). This apparent paradox can be better under-
stood in Fig. 1, where we have plotted the median adher-
ence rate to BDP against the levels of asthma control
(controlled or uncontrolled) at each follow-up visit.
The box-plot shows a consistent, dose-response gradient
for the adherence rate and the level of asthma control in
the three moments of the clinical-functional assessment. In
other words, the level of control is always better in patients
with higher adherence rate (p  0.001). Our results suggest
that the clinical and/or functional control of mild to
moderate persistent asthma might be possible with at least
45e60% adherence rate to the adopted BDP-CFC thera-
peutic regimens, i.e., 225 mg (45% out of 500 mg) to 300 mg
(60% out of 500 mg) daily.
Table 3 shows the results of the final multivariate anal-
ysis model, which should be interpreted alongside the data
from the mean adherence rates for each step in the two
categories of asthma control, as shown in Fig. 1AeC.
Multivariate analysis showed that the level of asthma
control was consistently and independently related to theadherence rate in all three visits (p-values equal or lower
than 0.005). There was also a trend toward statistical
significance between controlled/uncontrolled asthma and
mother’s schooling level in the 8th month of follow-up.
Table 3 Multivariate analysis final model at the time of each follow-up visit.
Predictor 4th month
OR (95% CI; p-value)
8th month
OR (95% CI; p-value)
12th month
OR (95% CI; p-value)
Adherence rate 0.97
(0.94e0.99; 0.005)
0.96
(0.94e0.99; 0.001)
0.94
(0.92e0.99; 0.001)
Mother’s schooling level NS 1.14a
(0.99e1.31; 0.1)
NS
NS Z not statistically significant.
a trend toward statistical significance.
342 N.S. Jentzsch et al.There was no association with other co-variables, i.e., sex,
age group, parents’ schooling level, asthma duration,
asthma severity, previous emergency room visits and
hospitalization before protocol admission.
Discussion
To the best of our knowledge, this is the first prospective
randomized medium term study that assessed the rela-
tionship between level of asthma control and adherence
rate to BDP, measured exclusively through an electronic
monitor in children and adolescents. This is the main clin-
ical importance and novelty of our findings. However, the
lack of similar studies, unfortunately, hinders more
detailed comparisons with our results.
In clinical practice, if an optimal level of asthma control
is not achieved, the adherence rate to anti-asthmatic
drugs, among other factors, must be checked before
prescribing a higher dose of inhaled steroids, combined or
not with an add-on medication.
Electronic monitors attached to pMDIs are the most
reliable method for assessing adherence to ICS.9,10 The
accuracy of Doser CT, a pressure-actuated monitor of
metered-dose inhaler usage, has been demonstrated in
a field study in which there was 91e96% agreement
between the device and actual use.12 The few studies in
which electronic monitors were used to track adherence to
ICS have always shown lower adherence rates than those
reported by the patient and family, pharmacy records and
canister weight.9e14 Even though there is not an ideal way
to measure ICS adherence, this method is considered the
most accurate, the exception being times when the patient
might deliberately actuate the pMDI without actually
inhaling the medication.
As demonstrated by others, an adherence rate to ICS by
40%e50% was enough to obtain asthma control.7,13
Approximate results were verified in a study with adult
patients6 and in another with children aged 1e16 years,
whose 32% adherence rate was verified through parent
report.8 In a meta-analysis of 10 works recruiting pediatric
patients carried out by Bender et al., one of the studies,
with a follow-up of only three months, subjects who
experienced exacerbations had a median ICS adherence
rate of 14%, whereas those with controlled asthma had
a median adherence rate of 68%.15 The authors point out
that the wide-ranging disparity in adherence emphasizes
the need to use more reliable measures to distinguish
between patients who adhere to the therapeutic regimenand those who do not, both in clinical practice and in
research.16 It is worth noting that adherence rates of
30e70% verified through different methods (electronic
monitoring, among others) and in different age groups have
led to satisfactory asthma control.16e22
Even though they had different aims, Pedersen et al. in
one of the few studies with children, reported results in the
same direction as ours. They followed 19 children, aged
6e15 years with moderate and severe asthma, taking
budesonide for four weeks. The use of half (i.e. 100 mg/day
of budesonide) of the prescribed dose e verified by canister
weight e was sufficient to control their symptoms. The
authors concluded that low doses of budesonide e which
have a similar anti-inflammatory effect than BDP, had
a marked anti-asthma efficacy in children.23
Our work has some clinical implications. Firstly, both
adherence rate to ICS and level of asthma control must be
systematically checked in scheduled and non-scheduled
appointments. Secondly, our results suggest that to attain
asthma control in children and adolescents, the adherence
rate can in fact be lower than the ideal 100%, since in our
prospective medium term cohort study, a minimum of 60%
adherence to the adopted BDP regimen (i.e., by 300 mg
daily) was enough to achieve asthma control, as defined by
symptoms e including exercise induced asthma e and lung
function. It is important to stress that in our patients the
adherence rate needed to obtain FEV1 superior to 80e90%
of predicted values was approximately the same (45%e60%)
needed to attain symptom control.
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